Skip to main content

Qiagen Value Stock - Dividend - Research Selection

Qiagen

ISIN: NL0012169213 , WKN: A2DKCH

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Qiagen Announces That QIAGEN Digital Insights Bioinformatics Business And Its Curated Knowledge Bases And Bioinformatics Expertise Will Be Integrating NVIDIA Accelerated Computing And The NVIDIA Bionemo Platform To Help Researchers Use AI More Effectively In Drug Discovery

2026-05-19
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and

Stifel Maintains Hold on Qiagen, Lowers Price Target to $36

2026-05-18
Stifel analyst Daniel Arias maintains Qiagen (NYSE:QGEN) with a Hold and lowers the price target from $50 to $36.

Qiagen N.V. (QGEN) Price Target Decreased by 13.91% to 46.28

2026-05-14

QGEN Investor Alert: Levi & Korsinsky Investigates Qiagen (QGEN) for Potential Securities Fraud

2026-05-13
Qiagen's forward-looking non-GAAP guidance lacked required GAAP reconciliations under SEC Regulation S-K Item 10 -- institutional investors who relied on these figures for portfolio allocation...

Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

2026-05-13
Qiagen N.V. (QGEN) Bank of America Global Healthcare Conference 2026 May 12, 2026 6:00 PM EDTCompany ParticipantsRoland Sackers - CFO, MD & Member of...

Transcript : Qiagen N.V. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03

2026-05-13
Presenter SpeechMichael Ryskin Thanks for joining us for our next session. My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team, and we're excited to be

Qiagen N.V. Proposes Annual Cash Dividend, Payable on July 14, 2026

2026-05-12
Qiagen N.V. at the Annual General Meeting, to be held on June 24, 2026 proposed a 40% increase in its annual cash dividend to $0.35 per ordinary share, compared with the initial annual dividend of...

Qiagen N.V. Announces Metin Colpan Decides Not to Stand for Re-Election of Supervisory Board

2026-05-12
Qiagen N.V. announced Dr. Metin Colpan has decided to conclude his service on the Supervisory Board at the Annual General Meeting and will not stand for re-election. In recognition of his...

Qiagen N : 2025 Annual Report 2025 Annual Financial Report

2026-05-12
QIAGEN N.V. Annual Report 2025 QIAGEN N.V. | Annual Report 2025 Overview Management Report Corporate Governance Financial Statements Appendices Page...

Qiagen N : 2025 Remuneration Report

2026-05-12
QIAGEN N.V. Remuneration Report 2025 Remuneration Report x Message from the Chair of the Compensation ...